A new target and compounds for treating age-related macular degeneration
blindness, age-related macular degeneration, new chemical entities, CD36, new target
The technology is a unique class of selective CD36 modulators that are novel drug candidates for treating age-related macular degeneration (AMD). Besides being the first class of specific CD36 modulator, the technology introduces a new approach for treating AMD by aiming at a new biological target.
Nanotech 2008 Conference Program Abstract